Literature DB >> 20060595

A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs.

V Kraig Abrams1, Billanna Hwang, Marina Lesnikova, M John Gass, Elizabeth Wayner, Cristina Castilla-Llorente, George E Georges, Richard A Nash.   

Abstract

A monoclonal antibody (mAb), P4A10, was made to the canine interleukin-2 receptor alpha chain (IL-2Ralpha; p55; Tac antigen; CD25) to facilitate studies of canine regulatory T-cells (Treg). By non-reduced Western blot, P4A10 bound to a 55kDa protein, the size of human IL-2Ralpha. In flow cytometry assays, it reacted with a minor population of circulating dog CD3(+)CD4(+) T-cells and the majority (>60%) of in vitro PMA-Ionomycin (PMA-IO)-activated canine CD3(+) T-cells. P4A10 recognized a hematopoietic cell population enriched for FoxP3+ cells as measured by flow cytometry. The P4A10-selected fractions of T-cells had significantly increased copy numbers of CD25, FoxP3, IL-10, and TGFbeta as detected by RT-PCR (reverse transcriptase-PCR) compared to the negative fractions. The P4A10-selected cells inhibited (3)H (tritiated) thymidine incorporation in a mixed leukocyte reaction (MLR) containing responders of the same origin. P4A10-selected T-cells from fresh peripheral blood mononuclear cells had less FoxP3 (p=0.07) by qRT-PCR (quantitative RT-PCR) and were less suppressive (p=0.01) than in vitro alloantigen-activated Treg. The mAb P4A10 is specific for canine CD25 and can be used to facilitate studies of CD25+FoxP3+ Treg in this clinically relevant large animal model. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20060595      PMCID: PMC2864801          DOI: 10.1016/j.vetimm.2009.12.006

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  33 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

2.  Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Authors:  Unsong Oh; Gregg Blevins; Caitlin Griffith; Nancy Richert; Dragan Maric; C Richard Lee; Henry McFarland; Steven Jacobson
Journal:  Arch Neurol       Date:  2009-04

3.  A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor.

Authors:  W J Leonard; J M Depper; T Uchiyama; K A Smith; T A Waldmann; W C Greene
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

Review 4.  Advances in interleukin 2 receptor targeted treatment.

Authors:  J C Morris; T A Waldmann
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

6.  The antibody against human CD25, ACT-1, recognizes canine T-lymphocytes in the G2/M and G0/G1 phases of the cell cycle during proliferation.

Authors:  Kenichi Masuda; Nobutaka Yasuda
Journal:  J Vet Med Sci       Date:  2008-11       Impact factor: 1.267

7.  Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.

Authors:  William W Busse; Elliot Israel; Harold S Nelson; James W Baker; B Lauren Charous; Donald Y Young; Vladimir Vexler; Richard S Shames
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

8.  High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

Authors:  Steven Yeh; Keith Wroblewski; Ronald Buggage; Zhuqing Li; Shree K Kurup; Hatice Nida Sen; Sam Dahr; Pushpa Sran; George F Reed; Randy Robinson; Jack A Ragheb; Thomas A Waldmann; Robert B Nussenblatt
Journal:  J Autoimmun       Date:  2008-06-20       Impact factor: 7.094

Review 9.  Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.

Authors:  E Bien; A Balcerska
Journal:  Biomarkers       Date:  2008-02       Impact factor: 2.658

10.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Gregg Blevins; Silva Markovic-Plese; Jennifer McCartin; Joseph A Frank; Jens Würfel; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

View more
  12 in total

1.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Authors:  Jonathan D Finn; Margareth C Ozelo; Denise E Sabatino; Helen W G Franck; Elizabeth P Merricks; Julie M Crudele; Shangzhen Zhou; Haig H Kazazian; David Lillicrap; Timothy C Nichols; Valder R Arruda
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

2.  The Use of Ex Vivo Generated Regulatory T-Cell Preparations in a Canine Lung Allograft Model.

Authors:  Kraig V Abrams; Billanna Hwang; Richard A Nash; George E Georges; Wayne Lamm; Barry Storer; David K Madtes; Robert Glenny; Michael S Mulligan
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

3.  Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation.

Authors:  Scott S Graves; Diane M Stone; Carol Loretz; Laura J Peterson; Marina Lesnikova; Billanna Hwang; George E Georges; Richard Nash; Rainer Storb
Journal:  Transplantation       Date:  2011-04-27       Impact factor: 4.939

4.  Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.

Authors:  Dammy Pinheiro; Yogesh Singh; Charlotte R Grant; Richard C Appleton; Flavio Sacchini; Kate R L Walker; Alden H Chadbourne; Charlotte A Palmer; Elizabeth Armitage-Chan; Ian Thompson; Lina Williamson; Fiona Cunningham; Oliver A Garden
Journal:  Immunology       Date:  2010-09-30       Impact factor: 7.397

5.  EFFECT OF LIPOSOMAL CLODRONATE-DEPENDENT DEPLETION OF PROFESSIONAL ANTIGEN PRESENTING CELLS ON NUMBERS AND PHENOTYPE OF CANINE CD4+CD25+FOXP3+ REGULATORY T CELLS.

Authors:  Kriston F Weaver; John V Stokes; Sagen A Gunnoe; Joyce S Follows; Lydia Shafer; Mais G Ammari; Todd M Archer; John M Thomason; Andrew J Mackin; Lesya M Pinchuk
Journal:  J Vet Med Res       Date:  2014-06-09

6.  In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate.

Authors:  Jennifer L Gori; Brian C Beard; Nathaniel P Williams; Christina Ironside; Debra Swanson; R Scott McIvor; Hans-Peter Kiem
Journal:  J Gene Med       Date:  2013 Jun-Jul       Impact factor: 4.565

7.  Immunohistochemical investigation of Foxp3 expression in the intestine in healthy and diseased dogs.

Authors:  Johannes Junginger; Ulrike Schwittlick; Frederik Lemensieck; Ingo Nolte; Marion Hewicker-Trautwein
Journal:  Vet Res       Date:  2012-03-22       Impact factor: 3.683

8.  Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice.

Authors:  Ying Wu; Yu-Mei Chang; Anneliese J Stell; Simon L Priestnall; Eshita Sharma; Michelle R Goulart; John Gribben; Dong Xia; Oliver A Garden
Journal:  Sci Rep       Date:  2019-09-17       Impact factor: 4.379

Review 9.  The immunopathology of sepsis: pathogen recognition, systemic inflammation, the compensatory anti-inflammatory response, and regulatory T cells.

Authors:  D H Lewis; D L Chan; D Pinheiro; E Armitage-Chan; O A Garden
Journal:  J Vet Intern Med       Date:  2012-03-17       Impact factor: 3.333

10.  In Vitro Influence of Mycophenolic Acid on Selected Parameters of Stimulated Peripheral Canine Lymphocytes.

Authors:  Maciej Guzera; Lidia Szulc-Dąbrowska; Anna Cywińska; Joy Archer; Anna Winnicka
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.